Chronoscale Holdings Corp quarterly report, Q2 FY2023

Filing summary

Registrant: The filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp as stated in the request metadata. This is an unaudited Form 10-Q for the quarter ended June 30, 2023, filed July 27, 2023. Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise indicated.

Business context and reporting period

Ekso designs and sells exoskeletons for medical rehabilitation and industrial applications. Its EksoHealth segment includes EksoNR and the Indego product line acquired from Parker Hannifin in December 2022; EksoWorks focuses on industrial devices, including EVO. The report compares the three and six months ended June 30, 2023 with the same periods in 2022.

Financial performance and liquidity

MetricQ2 2023Q2 2022Six months 2023Six months 2022
Revenue$4.703m$3.465m$8.825m$6.032m
Gross profit / margin$2.254m / 48%$1.641m / 47%$4.254m / 48%$2.850m / 47%
Operating expenses$6.538m$4.870m$12.986m$10.316m
Operating loss$(4.284)m$(3.229)m$(8.732)m$(7.466)m
Net loss$(4.230)m$(2.978)m$(8.619)m$(7.598)m
Loss per share, basic and diluted$(0.31)$(0.23)$(0.64)$(0.59)
Cash used in operating activitiesNot presented quarterly$(7.117)m$(8.454)m
  • Revenue growth was driven by EksoHealth device sales, particularly EksoNR and Indego. EksoWorks revenue declined, including from lower EVO sales and contract-manufacturer transition delays.
  • Operating expenses increased, principally from HMC-related staffing, research, marketing, legal and integration costs. Gross margin improved modestly, which management attributed mainly to lower device costs.
  • Cash and restricted cash were $13.307m at June 30, 2023, including $2.0m restricted under the Pacific Western Bank loan covenant; management reported approximately $11.3m of effective unrestricted cash. Working capital was $14.6m, down from $21.8m at December 31, 2022.
  • Balance-sheet notes payable, net, totaled $6.238m ($2.937m current and $3.301m non-current). The PWB loan had $2.0m principal due August 13, 2023. The separate $5.0m Parker note is unsecured, subordinated, non-interest-bearing by its terms, and payable in quarterly installments beginning December 2023; it was recorded at a discounted carrying value.

Material changes versus the prior comparable period

  • Q2 revenue rose 36%; first-half revenue rose 46%. EksoHealth growth more than offset weaker EksoWorks performance.
  • First-half gross margin rose to 48% from 47%, while first-half operating loss widened to $8.732m from $7.466m and net loss widened to $8.619m from $7.598m.
  • First-half operating cash use improved to $7.117m from $8.454m, but cash and restricted cash fell by $7.218m during the first half, to $13.307m.
  • The HMC acquisition expanded the medical-device portfolio but added operating costs and Parker-note obligations. Common shares outstanding increased to 13.807m from 13.203m at year-end.

Outlook, risks and unusual items

  • Going concern: Management concluded substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. It expects operating losses and negative operating cash flows and says additional financing is needed. Management’s plans to raise capital and reduce costs do not alleviate the doubt because the expense-reduction plan was considered reasonably possible, but not probable.
  • Management said June 30 cash was expected to fund operations into Q2 2024, but also stated it did not believe cash and restricted cash would fund operations for the next 12 months. Potential funding routes include equity or ATM offerings, debt, and receivables factoring; none is assured. The company may defer or abandon development projects and reduce costs if financing is insufficient.
  • The PWB term loan’s $2.0m principal matured August 13, 2023. A July 2023 amendment extended a separate restriction concerning foreign subsidiary cash through that date; the filing does not say that the amendment extended the loan maturity.
  • Management highlighted hospital budget pressure, inflation, staffing and supply-chain constraints, long sales cycles, reimbursement uncertainty, competition, regulatory and clinical requirements, customer concentration, foreign-exchange exposure, and dependence on additional capital. Three customers each represented at least 10% of Q2 revenue; one customer represented 13% of receivables at quarter-end.
  • Warrant revaluation gains were $0.152m in Q2 2023 versus $0.999m in Q2 2022, and $0.126m versus $0.899m for the respective first halves. These noncash gains are affected by share price and valuation assumptions. Q2 2022 also included a $0.718m foreign-exchange loss; Q2 2023 foreign-exchange loss was minimal.
  • Purchase obligations were $3.455m, expected to be paid within one year; total listed contractual obligations were $11.863m. Management said inventory stockpiling to manage supplier disruption can adversely affect near-term cash use.
  • No formal revenue or earnings guidance was provided. Management reported booking 44 EksoHealth units in Q2 and revenue of $4.7m, up 36% year over year. The filing says disclosure controls were effective and reports no material change in internal control over financial reporting.

Important facts for investors to verify

  • Confirm the registrant identity and ticker: the supplied metadata names Chronoscale, but the filing identifies Ekso Bionics Holdings, Inc. (EKSO).
  • Check whether the August 13, 2023 PWB maturity was repaid, refinanced, or otherwise amended, and the resulting unrestricted cash and covenant position.
  • Track financing availability, dilution or senior claims from new capital, actual cash burn, and whether the company’s stated runway and cost-reduction plans remain achievable.
  • Assess whether EksoHealth growth can continue and improve profitability, and whether EVO manufacturing delays and EksoWorks declines are resolved.
  • Review HMC integration costs, the preliminary purchase-price allocations, Parker-note payments, and potential acquisition-related obligations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.